ETHERNIAWhat is the ageing hypothesis?
Metformin is used to lower glucose in type 2 diabetes. Longevity research asks whether its broader metabolic effects could delay several diseases together. In MILES, researchers examined muscle and adipose gene expression rather than waiting for clinical events. Pathway changes are evidence of biological activity; they cannot establish that a person has become younger. [1]
Animals: the exposure is part of the result
A mouse study found benefits with 0.1% metformin in food, while a higher 1% exposure was toxic. This is a warning against treating “more pathway activation” as automatically better. Dietary concentration in a mouse is not a human dose, and species-specific pharmacology limits direct translation. [2]
Humans: an informative but small experiment
MILES enrolled 14 older adults with impaired glucose tolerance and compared metformin with placebo in a crossover design. The molecular results inform mechanism, not disability, mortality or maximum lifespan. A study that is well suited to finding tissue-level changes may be far too small to estimate clinical benefit. [1]
Why combination trials matter
MASTERS found that metformin blunted muscle hypertrophy during resistance training in older adults. That does not mean the drug is inappropriate for diabetes, or that every exercise adaptation is lost. It does show why a collection of individually attractive interventions needs testing as a combination. A longevity strategy must consider what is gained and what might be displaced. [3]
Studied exposure and specific risks
MILES studied 1,700 mg daily over short treatment periods. This describes a research exposure, not a longevity prescription. The clinical label identifies gastrointestinal intolerance, vitamin B12 deficiency and lactic-acidosis risk in susceptible settings, including substantial renal impairment. A long history of medical use helps identify risks; it does not establish a favourable trade-off in healthy people. [1] [4]
Trial watch: the question TAME is designed to ask
The TAME programme proposes testing whether metformin delays a collection of age-related clinical outcomes. Its programme page is the appropriate place to check launch and funding information; a planned trial is not an efficacy result. Ethernia is not presenting TAME as completed, recruiting or successful without a corresponding verified record. [5]
What would change our view?
A sufficiently powered randomized trial in the intended population, with a prespecified clinical composite, would be materially more informative than another molecular signature. Components of the composite should also be reported separately: delaying one diagnosis is not equivalent to improving every aspect of ageing. Disability, treatment discontinuation and interactions with training belong in that assessment.
Sources & study records
- Kulkarni et al. (2018). Metformin regulates metabolic and nonmetabolic pathways in skeletal muscle and subcutaneous adipose tissues of older adultsAging Cell · Small randomized crossover study
- Martin-Montalvo et al. (2013). Metformin improves healthspan and lifespan in miceNature Communications · Animal experiment
- Walton et al. (2019). Metformin blunts muscle hypertrophy in response to progressive resistance exercise training in older adults: The MASTERS trialAging Cell · Randomized controlled trial
- Manufacturer label (2026). Metformin hydrochloride prescribing informationDailyMed · Drug safety reference
- American Federation for Aging Research (2026). Targeting Aging with MetforminStudy programme information · Programme description; not results
Evidence reviewed 2026-09-16. Registry status can change; follow the linked record for current details.